Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina; Rosetta Genomics; Chronix Biomedical; Caris Life Sciences; Babraham Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina announced this week that it has cut the price on its individual genome sequencing service to $19,500. The firm also said that the price would be $14,500 per genome for groups of five participants using the same physician. Last June, Illumina partnered with four consumer genomics firms to bring whole-genome sequencing analysis of genetic risk information to customers. The initial cost of the service was $48,000.


Rosetta Genomics this week formed a majority-owned subsidiary called Rosetta Green, which is focused on microRNA-based agricultural and clean technology applications. Rosetta said that it holds a 76 percent stake in the new subsidiary. Rosetta Green also has received $1.5 million in funding from outside investors and has received funding from the Israeli Office of the Chief Scientist.


Chronix Biomedical said that it has launched a new disease detection and monitoring service for cancer researchers using its Apoptotic DNA Blood Test, which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.


Caris Life Sciences said this week that it has moved into a new corporate headquarters in the Dallas area that is three times larger than its previous facility. It also said that it has tripled its space in Phoenix with a new facility that conducts R&D on molecular tests for cancer.


Researchers at the Babraham Institute have been awarded a £900,000 ($1.3 million) grant to conduct studies in epigenetic regulation in partnership with biotech firm CellCentric. The funding is being provided by the UK's Biotechnology and Biological Sciences Research Council.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.